INSIGHT FLU005: An anti-influenza virus hyperimmune intravenous immunoglobulin pilot study

Richard T. Davey, Norman Markowitz, John Beigel, Deborah Wentworth, Abdel Babiker, Tauseef Rehman, Robin Dewar, Julia Metcalf, Timothy M. Uyeki, Elizabeth B. Finley, Barbara Standridge, Paul F. Riska, H. Clifford Lane, Fred Gordin, James D. Neaton, E. Denning, A. Duchene, N. Engen, M. Harrison, K. QuanG. Thompson, Adriana Sanchez, Marie Hoover, Venn Natarajan, H. Preston Holley, John Tierney, Jocelyn Voell, J. Baxter, D. Bigley, P. Coburn, L. Faber, E. Gardner, L. Harlow, M. Jain, L. Makohon, R. Mcconnell, J. Moghe, R. Nahra, B. Omotosho, T. Petersen, H. Polenakovik, S. Rizza, J. Scott, A. Shoen, C. Solorzano, Z. Temesgen, J. Whitaker

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Hemagglutination inhibition (HAI) antibody responses to anti-influenza virus hyperimmune intravenous immunoglobulin (hIVIG) were characterized. Thirty-one patients with influenza during the 2013-2014 season were randomly assigned to receive 0.25 g/kg of hIVIG (n = 16) or placebo (n = 15). For hIVIG recipients, the ratio of geometric mean titers (1 hour after infusion/before infusion) was 4.00 (95% confidence interval [CI], 2.61-6.13) for 2009 pandemic influenza A(H1N1) and 1.76 (95% CI, 1.33-2.32) for influenza A(H3N2) and influenza B. Among patients with 2009 pandemic influenza A(H1N1), ratios for hIVIG (n = 9) versus placebo (n = 8) were higher 1 hour after infusion (3.9 [95% CI, 2.3-6.7]) and sustained through day 3 (2.0 [95% CI, 1.0-4.0]). hIVIG administration significantly increases HAI titer levels among patients with influenza, supporting the need to perform a clinical outcomes study. Clinical trials registration: NCT02008578.

Original languageEnglish (US)
Pages (from-to)574-578
Number of pages5
JournalJournal of Infectious Diseases
Volume213
Issue number4
DOIs
StatePublished - Feb 15 2016

Fingerprint

Intravenous Immunoglobulins
Orthomyxoviridae
Human Influenza
Confidence Intervals
Hemagglutination
Pandemics
Placebos
Intravenous Administration
Antibody Formation
Outcome Assessment (Health Care)
Clinical Trials

Keywords

  • anti-influenza virus hIVIG
  • antibody titers
  • influenza
  • randomized trial

ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Allergy

Cite this

Davey, R. T., Markowitz, N., Beigel, J., Wentworth, D., Babiker, A., Rehman, T., ... Whitaker, J. (2016). INSIGHT FLU005: An anti-influenza virus hyperimmune intravenous immunoglobulin pilot study. Journal of Infectious Diseases, 213(4), 574-578. https://doi.org/10.1093/infdis/jiv453

INSIGHT FLU005 : An anti-influenza virus hyperimmune intravenous immunoglobulin pilot study. / Davey, Richard T.; Markowitz, Norman; Beigel, John; Wentworth, Deborah; Babiker, Abdel; Rehman, Tauseef; Dewar, Robin; Metcalf, Julia; Uyeki, Timothy M.; Finley, Elizabeth B.; Standridge, Barbara; Riska, Paul F.; Lane, H. Clifford; Gordin, Fred; Neaton, James D.; Denning, E.; Duchene, A.; Engen, N.; Harrison, M.; Quan, K.; Thompson, G.; Sanchez, Adriana; Hoover, Marie; Natarajan, Venn; Holley, H. Preston; Tierney, John; Voell, Jocelyn; Baxter, J.; Bigley, D.; Coburn, P.; Faber, L.; Gardner, E.; Harlow, L.; Jain, M.; Makohon, L.; Mcconnell, R.; Moghe, J.; Nahra, R.; Omotosho, B.; Petersen, T.; Polenakovik, H.; Rizza, S.; Scott, J.; Shoen, A.; Solorzano, C.; Temesgen, Z.; Whitaker, J.

In: Journal of Infectious Diseases, Vol. 213, No. 4, 15.02.2016, p. 574-578.

Research output: Contribution to journalArticle

Davey, RT, Markowitz, N, Beigel, J, Wentworth, D, Babiker, A, Rehman, T, Dewar, R, Metcalf, J, Uyeki, TM, Finley, EB, Standridge, B, Riska, PF, Lane, HC, Gordin, F, Neaton, JD, Denning, E, Duchene, A, Engen, N, Harrison, M, Quan, K, Thompson, G, Sanchez, A, Hoover, M, Natarajan, V, Holley, HP, Tierney, J, Voell, J, Baxter, J, Bigley, D, Coburn, P, Faber, L, Gardner, E, Harlow, L, Jain, M, Makohon, L, Mcconnell, R, Moghe, J, Nahra, R, Omotosho, B, Petersen, T, Polenakovik, H, Rizza, S, Scott, J, Shoen, A, Solorzano, C, Temesgen, Z & Whitaker, J 2016, 'INSIGHT FLU005: An anti-influenza virus hyperimmune intravenous immunoglobulin pilot study', Journal of Infectious Diseases, vol. 213, no. 4, pp. 574-578. https://doi.org/10.1093/infdis/jiv453
Davey RT, Markowitz N, Beigel J, Wentworth D, Babiker A, Rehman T et al. INSIGHT FLU005: An anti-influenza virus hyperimmune intravenous immunoglobulin pilot study. Journal of Infectious Diseases. 2016 Feb 15;213(4):574-578. https://doi.org/10.1093/infdis/jiv453
Davey, Richard T. ; Markowitz, Norman ; Beigel, John ; Wentworth, Deborah ; Babiker, Abdel ; Rehman, Tauseef ; Dewar, Robin ; Metcalf, Julia ; Uyeki, Timothy M. ; Finley, Elizabeth B. ; Standridge, Barbara ; Riska, Paul F. ; Lane, H. Clifford ; Gordin, Fred ; Neaton, James D. ; Denning, E. ; Duchene, A. ; Engen, N. ; Harrison, M. ; Quan, K. ; Thompson, G. ; Sanchez, Adriana ; Hoover, Marie ; Natarajan, Venn ; Holley, H. Preston ; Tierney, John ; Voell, Jocelyn ; Baxter, J. ; Bigley, D. ; Coburn, P. ; Faber, L. ; Gardner, E. ; Harlow, L. ; Jain, M. ; Makohon, L. ; Mcconnell, R. ; Moghe, J. ; Nahra, R. ; Omotosho, B. ; Petersen, T. ; Polenakovik, H. ; Rizza, S. ; Scott, J. ; Shoen, A. ; Solorzano, C. ; Temesgen, Z. ; Whitaker, J. / INSIGHT FLU005 : An anti-influenza virus hyperimmune intravenous immunoglobulin pilot study. In: Journal of Infectious Diseases. 2016 ; Vol. 213, No. 4. pp. 574-578.
@article{a6b91510b05b4b75844fada10b40b76e,
title = "INSIGHT FLU005: An anti-influenza virus hyperimmune intravenous immunoglobulin pilot study",
abstract = "Hemagglutination inhibition (HAI) antibody responses to anti-influenza virus hyperimmune intravenous immunoglobulin (hIVIG) were characterized. Thirty-one patients with influenza during the 2013-2014 season were randomly assigned to receive 0.25 g/kg of hIVIG (n = 16) or placebo (n = 15). For hIVIG recipients, the ratio of geometric mean titers (1 hour after infusion/before infusion) was 4.00 (95{\%} confidence interval [CI], 2.61-6.13) for 2009 pandemic influenza A(H1N1) and 1.76 (95{\%} CI, 1.33-2.32) for influenza A(H3N2) and influenza B. Among patients with 2009 pandemic influenza A(H1N1), ratios for hIVIG (n = 9) versus placebo (n = 8) were higher 1 hour after infusion (3.9 [95{\%} CI, 2.3-6.7]) and sustained through day 3 (2.0 [95{\%} CI, 1.0-4.0]). hIVIG administration significantly increases HAI titer levels among patients with influenza, supporting the need to perform a clinical outcomes study. Clinical trials registration: NCT02008578.",
keywords = "anti-influenza virus hIVIG, antibody titers, influenza, randomized trial",
author = "Davey, {Richard T.} and Norman Markowitz and John Beigel and Deborah Wentworth and Abdel Babiker and Tauseef Rehman and Robin Dewar and Julia Metcalf and Uyeki, {Timothy M.} and Finley, {Elizabeth B.} and Barbara Standridge and Riska, {Paul F.} and Lane, {H. Clifford} and Fred Gordin and Neaton, {James D.} and E. Denning and A. Duchene and N. Engen and M. Harrison and K. Quan and G. Thompson and Adriana Sanchez and Marie Hoover and Venn Natarajan and Holley, {H. Preston} and John Tierney and Jocelyn Voell and J. Baxter and D. Bigley and P. Coburn and L. Faber and E. Gardner and L. Harlow and M. Jain and L. Makohon and R. Mcconnell and J. Moghe and R. Nahra and B. Omotosho and T. Petersen and H. Polenakovik and S. Rizza and J. Scott and A. Shoen and C. Solorzano and Z. Temesgen and J. Whitaker",
year = "2016",
month = "2",
day = "15",
doi = "10.1093/infdis/jiv453",
language = "English (US)",
volume = "213",
pages = "574--578",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - INSIGHT FLU005

T2 - An anti-influenza virus hyperimmune intravenous immunoglobulin pilot study

AU - Davey, Richard T.

AU - Markowitz, Norman

AU - Beigel, John

AU - Wentworth, Deborah

AU - Babiker, Abdel

AU - Rehman, Tauseef

AU - Dewar, Robin

AU - Metcalf, Julia

AU - Uyeki, Timothy M.

AU - Finley, Elizabeth B.

AU - Standridge, Barbara

AU - Riska, Paul F.

AU - Lane, H. Clifford

AU - Gordin, Fred

AU - Neaton, James D.

AU - Denning, E.

AU - Duchene, A.

AU - Engen, N.

AU - Harrison, M.

AU - Quan, K.

AU - Thompson, G.

AU - Sanchez, Adriana

AU - Hoover, Marie

AU - Natarajan, Venn

AU - Holley, H. Preston

AU - Tierney, John

AU - Voell, Jocelyn

AU - Baxter, J.

AU - Bigley, D.

AU - Coburn, P.

AU - Faber, L.

AU - Gardner, E.

AU - Harlow, L.

AU - Jain, M.

AU - Makohon, L.

AU - Mcconnell, R.

AU - Moghe, J.

AU - Nahra, R.

AU - Omotosho, B.

AU - Petersen, T.

AU - Polenakovik, H.

AU - Rizza, S.

AU - Scott, J.

AU - Shoen, A.

AU - Solorzano, C.

AU - Temesgen, Z.

AU - Whitaker, J.

PY - 2016/2/15

Y1 - 2016/2/15

N2 - Hemagglutination inhibition (HAI) antibody responses to anti-influenza virus hyperimmune intravenous immunoglobulin (hIVIG) were characterized. Thirty-one patients with influenza during the 2013-2014 season were randomly assigned to receive 0.25 g/kg of hIVIG (n = 16) or placebo (n = 15). For hIVIG recipients, the ratio of geometric mean titers (1 hour after infusion/before infusion) was 4.00 (95% confidence interval [CI], 2.61-6.13) for 2009 pandemic influenza A(H1N1) and 1.76 (95% CI, 1.33-2.32) for influenza A(H3N2) and influenza B. Among patients with 2009 pandemic influenza A(H1N1), ratios for hIVIG (n = 9) versus placebo (n = 8) were higher 1 hour after infusion (3.9 [95% CI, 2.3-6.7]) and sustained through day 3 (2.0 [95% CI, 1.0-4.0]). hIVIG administration significantly increases HAI titer levels among patients with influenza, supporting the need to perform a clinical outcomes study. Clinical trials registration: NCT02008578.

AB - Hemagglutination inhibition (HAI) antibody responses to anti-influenza virus hyperimmune intravenous immunoglobulin (hIVIG) were characterized. Thirty-one patients with influenza during the 2013-2014 season were randomly assigned to receive 0.25 g/kg of hIVIG (n = 16) or placebo (n = 15). For hIVIG recipients, the ratio of geometric mean titers (1 hour after infusion/before infusion) was 4.00 (95% confidence interval [CI], 2.61-6.13) for 2009 pandemic influenza A(H1N1) and 1.76 (95% CI, 1.33-2.32) for influenza A(H3N2) and influenza B. Among patients with 2009 pandemic influenza A(H1N1), ratios for hIVIG (n = 9) versus placebo (n = 8) were higher 1 hour after infusion (3.9 [95% CI, 2.3-6.7]) and sustained through day 3 (2.0 [95% CI, 1.0-4.0]). hIVIG administration significantly increases HAI titer levels among patients with influenza, supporting the need to perform a clinical outcomes study. Clinical trials registration: NCT02008578.

KW - anti-influenza virus hIVIG

KW - antibody titers

KW - influenza

KW - randomized trial

UR - http://www.scopus.com/inward/record.url?scp=84960156949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960156949&partnerID=8YFLogxK

U2 - 10.1093/infdis/jiv453

DO - 10.1093/infdis/jiv453

M3 - Article

C2 - 26374911

AN - SCOPUS:84960156949

VL - 213

SP - 574

EP - 578

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 4

ER -